Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: J Allergy Clin Immunol. 2023 Jun 13;152(5):1179–1195. doi: 10.1016/j.jaci.2023.05.026

Figure 7. Dupilumab treatment modestly affects lesional and non-lesional barrier function at later timepoints.

Figure 7.

(A) Changes in basal TEWL measurements in les and (B) NL skin sites. (C) The mean TEWL values obtained at NL skin site at Days 14 and 112 following five, ten and fifteen tape strips are shown for the dupilumab (green) and placebo (purple)-randomized populations to visualize how the AUC is calculated. (D) The longitudinal changes in TEWL AUC at NL skin sites.

AUC, area under the curve; les, lesional skin; NL, nonlesional skin; TEWL, transepidermal water loss.